对转录组数据的双网络分析,以发现非小细胞肺癌中新的治疗点
Yuquan Bai1, Lu Zhou1, Chuanfen Zhang1
1Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Oncogene
|October 20, 2023
概括
研究人员将PSMD2确定为非小细胞肺癌 (NSCLC) 的新疗法标. 博尔特佐米布通过向PSMD2有效地抑制NSCLC的扩散,为患者提供了潜在的新治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 非小细胞肺癌 (NSCLC) 药物治疗面临诸多挑战,包括副作用,耐药性和有限的患者群体.
- 确定新的治疗点对于改善NSCLC治疗结果至关重要.
研究的目的:
- 通过使用一种新的网络分析方法,发现NSCLC的新治疗点.
- 研究PSMD2作为治疗点的潜力,并评估博特佐米布对NSCLC的疗效.
主要方法:
- 开发了一种新的网络分析方法 (差异-相关-丰富-因果关系-节点).
- 分析了BEAS-2B和7个NSCLC细胞系的测序数据.
- 进行了基因淘汰,蛋白质表达分析,IPA,分子对接,体外和体内实验.
主要成果:
- 确定PSMD2作为细胞循环网络中的中心基因,与NSCLC预后相关.
- 通过诱导细胞循环停止和改变关键细胞循环蛋白质,PSMD2淘汰赛抑制了NSCLC的扩散.
- 博尔特佐米布表现出对PSMD2的强烈亲和力,并抑制了NSCLC的生长,包括耐药病例.
结论:
- PSMD2是NSCLC的一个有前途的治疗点.
- 博尔特佐米布有效向PSMD2,PSMB1和PSMB5,以抑制NSCLC的扩散.
- 博尔特佐米布对不同NSCLC患者群体来说是一个潜在的治疗选择.
更多相关视频
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K